Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Net Income Loss of $348.90 million for the year ending 2025.
- BIOMARIN PHARMACEUTICAL INC showed a decrease of -18.3% in Net Income Loss from 2024 to 2025.
- This data is from BIOMARIN PHARMACEUTICAL INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), BIOMARIN PHARMACEUTICAL INC's Net Income Loss has grown by 1,031.7%.
- Historical annual values: Fiscal year 2025: $348.90 million | Fiscal year 2024: $426.86 million | Fiscal year 2023: $167.65 million | Fiscal year 2022: $141.56 million | Fiscal year 2021: -$64.08 million | Fiscal year 2020: $854.03 million | Fiscal year 2019: -$23.85 million | Fiscal year 2018: -$77.21 million | Fiscal year 2017: -$117.04 million | Fiscal year 2016: -$630.21 million | Fiscal year 2015: -$171.80 million | Fiscal year 2014: -$133.97 million | Fiscal year 2013: -$176.35 million | Fiscal year 2012: -$114.35 million | Fiscal year 2011: -$53.84 million | Fiscal year 2010: $205.82 million | Fiscal year 2009: -$488.0 thousand | Fiscal year 2008: $30.83 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: